Give more independence to the Scots—paired with a statement that there will be no more votes for a long time to come
The move comes as GM's blue-chip brand is finally considered in range of—if not quite on par with—the best German luxury rides
Unresolved economic conflicts simmer during a tenuous cease-fire
In becoming Oracle's chairman and chief technology officer, Ellison will leave the software giant he founded in the hands of co-chief executive officers Mark Hurd and Safra Katz
The popular premixed funds are supposed to get more conservative as retirement gets closer. What “conservative” means is open to interpretation
With "activity-based working," you lose your desk and gain your freedom—all for better efficiency
The NFL is facing its worst crisis in 50 years. Why is Commissioner Goodell so sure he won't lose his job?
Two dozen live shows will broadcast professors' ideas for 40 hours a week, serving as a way to broaden Wharton's reach
A report finds high default rates on franchise loans
King of Prussia, Pa.
Founders: Dr. Robert Lefkowitz and Dr. Howard Rockman
VC Investment over the last four quarters: $26.1 million
Trevena, founded in January 2008, is a drug discovery company developing pharmaceuticals that target what are known as G-protein coupled receptors. Such drugs make up more than 40% of marketed drugs today, according to Trevena. The company's drug discovery platform is based on research from Duke University Medical Center, including that of founder and National Medal of Science winner Robert Lefkowitz.
Key to startup success: "We've been able to generate the strong investor support for this idea [because] the technology and the opportunity here is very, very unique, and the possibility of unlocking new areas of biology is so significantly different from what's currently out there."